Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expression.

Junge, Alexandra; Bacher, Vera Ulrike; Mueller, Beatrice U; Keller, Peter; Solenthaler, Max; Pabst Müller, Thomas Niklaus (2018). Adverse outcome of AML with aberrant CD16 and CD56 NK cell marker expression. (In Press). Hematological oncology Wiley 10.1002/hon.2516

[img] Text
VUB_Junge_et_al-2018-Hematological_Oncology.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (399kB) | Request a copy

Natural killer cells mediate antibody-dependent cell-mediated cytotoxicity, and CD16 exerts key functions to induce antibody-dependent cell-mediated cytotoxicity response. Because the prognostic relevance of aberrant CD16 expression in AML patients at diagnosis is unknown, we analyzed 325 AML patients undergoing intensive chemotherapy for aberrant CD16+ and CD56+ natural killer-cell marker expression. CD56+ AML patients had inferior median event-free (EFS; P = 0.0699) and overall survival (OS; 10.9 versus 20.6 months; P = 0.0132). Patients expressing CD16 had worse median EFS (P = 0.0622) and OS (13.0 versus 45.9 months; P = 0.0277). EFS for CD16+/CD56+ patients was 5.7 months compared with 7.1 months for CD16-/CD56- (P = 0.3690), and OS was 10.6 months for CD16+/CD56+ patients compared with 52.2 months for CD16-/CD56- patients (P = 0.0311). Patients with CD16+/CD56+ expression had a lower probability to achieve complete remission after 2 induction cycles (52% versus 72%). Our data suggest that AML patients with aberrant CD16 and CD56 expression have adverse survival outcomes.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Bacher, Vera Ulrike, Pabst, Thomas Niklaus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1099-1069

Publisher:

Wiley

Language:

English

Submitter:

Pierrette Durand Lüthi

Date Deposited:

04 Oct 2018 09:27

Last Modified:

02 Mar 2023 23:31

Publisher DOI:

10.1002/hon.2516

PubMed ID:

29862539

Uncontrolled Keywords:

AML CD16 CD56 NK cell immunophenotype prognosis response survival

BORIS DOI:

10.7892/boris.120294

URI:

https://boris.unibe.ch/id/eprint/120294

Actions (login required)

Edit item Edit item
Provide Feedback